Name:
`
` Address:
`
`
`
`
`
`
`
`
`
`
`
` Date of Birth:
`
` Place of Birth:
`
` Education:
`
`
`
`
`
`
`1978 B.A.
`
`
`
`1982 M.D.
`
`
`Curriculum Vitae
`
`William Curtis Biggs, MD, FACE, ECNU
`
`1215 South Coulter Street
`Suite 400
`Amarillo, TX 79106
`
`November 16, 1956
`
`Merced, California
`
`University of California, San Diego
`Chemistry, Magna cum Laude
`
`University of Texas
`Southwestern Medical School at Dallas
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1982-1983
`
`
`
`1983-1984
`
`
`
`
`
`1985-1986
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Intern in Medicine,
`University of California, San Diego
`
`Junior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Senior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Fellow in Endocrinology/Diabetes
`Joslin Diabetes Center, Boston
`New England Deaconess Hospital,
`Boston
`
`
` Post Doctoral Training:
` Internship and Residencies:
`
`
`
`
`
`
`
`
`1984-1985
`
`
`
`
`
`
`
` Fellowships:
`
`
`
`
`
`
` Licensure and Certification:
`
` Licenses:
`
` 1983
` 1984
`
`
`
`
`
` Texas Board of Medical Examiners (G3157)
` Massachusetts Registry
`
`(52237)
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
` Address:
`
`
`
`
`
`
`
`
`
`
`
` Date of Birth:
`
` Place of Birth:
`
` Education:
`
`
`
`
`
`
`1978 B.A.
`
`
`
`1982 M.D.
`
`
`Curriculum Vitae
`
`William Curtis Biggs, MD, FACE, ECNU
`
`1215 South Coulter Street
`Suite 400
`Amarillo, TX 79106
`
`November 16, 1956
`
`Merced, California
`
`University of California, San Diego
`Chemistry, Magna cum Laude
`
`University of Texas
`Southwestern Medical School at Dallas
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1982-1983
`
`
`
`1983-1984
`
`
`
`
`
`1985-1986
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Intern in Medicine,
`University of California, San Diego
`
`Junior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Senior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Fellow in Endocrinology/Diabetes
`Joslin Diabetes Center, Boston
`New England Deaconess Hospital,
`Boston
`
`
` Post Doctoral Training:
` Internship and Residencies:
`
`
`
`
`
`
`
`
`1984-1985
`
`
`
`
`
`
`
` Fellowships:
`
`
`
`
`
`
` Licensure and Certification:
`
` Licenses:
`
` 1983
` 1984
`
`
`
`
`
` Texas Board of Medical Examiners (G3157)
` Massachusetts Registry
`
`(52237)
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
` Board Certification:
`
` 1985
`
`
`2014
`
`
`
`
`
`Internal Medicine - American Board of Internal Medicine
`
`Clinical Informatics – American Board of Preventative Medicine
`
`Endocrine Certification Neck Ultrasound (ECNU)
`American College of Endocrinology
`
`
` Other Certifications:
`
` 2010
`
`
`
`
` Academic Appointments:
`
` 1983-1986 Clinical Fellow in Medicine
`
`
`
`
`
`Harvard Medical School, Boston
`
` 1986-
`
`
`
`
`
`
`
`
`
`
` Hospital Appointments:
`
` 1985-1986
`
`
`
`
` 1986-
`
`
`
`
`
`
`
`
`Clinical Assistant Professor
`
`
`Department of Internal Medicine
`
`
`Texas Tech School of Medicine,
`
`
`Amarillo
`
`New England Baptist Hospital, Boston
`
`Assistant to Chief of Medicine,
`
`Northwest Texas Hospital, Amarillo
`
`Quality Assurance Committee 1987-1989
`
`
`
`
`
`
`Nutrition Committee 1987-1995
`
`Chairman, 1988-1995
`
`Diabetes Center, Medical Advisor 1989- 1999,
`Medical Director 2004 - present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Department of Internal Medicine
`
`Chairman, 1989- 1993
`
`President of Medical Staff 1994-1995
`
`
`
`and 1995-1996
`
`Baptist St. Anthony’s Hospital, Amarillo
`(formerly High Plains Baptist Hospital)
`
`
`
`Director, Center for Diabetes Care 1988-1991
`
`
`
`
`
`
`
`
` 1986-
`
`
`
`
`
`Pharmacy & Therapeutics Committee 1988-1992
`
`
`
`
`
` Chairman 1990-1992
`
`
`
`
` Memberships in Professional Societies:
`
` 1983-2009
` 1984-1986
` 1986-
`
`
`American College of Physicians
`Massachusetts Medical Society
`Texas Medical Association
`
`2
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
` 1986-
`
` 1985-
`
`
`
` 1990-1998
` 1991-
`
` 1992-
`
`
`
`
` 2012-
`
`
`Current Positions
`
` 1995-
`
`
`
`
`
`
`
`
`
`
` 2012-
`
`
` 2010-
` 2014-
` 2015-
`
`
`
`
`
`
`
`
`
`1986-1995
`
`
`
`1988-1989
`
`1991-1994
`
`
`
` 2015-
`
`
` 2017 -
`
`
`
`
`Previous Positions
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1994
`
`
`
`
`
`1996 - 2004
`
`
`
`2005- 2011
`
`
`
`
`2009 - 2010
`
`
`
`Potter-Randall County Medical Society
`American Diabetes Association
`
`Council on Diabetes and Pregnancy
`American Society of Internal Medicine
`American Medical Association
`American Association of Clinical Endocrinologists (AACE)
`
`(Charter Member)
`American Medical Informatics Association
`
`Amarillo Medical Specialists, LLP
`Managing Partner and Chief Information Officer
`(Currently a 43 provider medical group)
`
`Amarillo Legacy Medical ACO
`CEO and Chief Medical Officer
`
`
`
`
`American Association of Clinical Endocrinologists
`Socioeconomics Committee
`IT Advisory Committee
`Business Opportunities Committee
`
`American Medical Association CPT Editorial Panel
`AMA CPT Reviewer / Advisor for AACE
`
`Amarillo Hospital District
`Board of Managers - Vice Chairman
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Medical Advisor to U.S. Department of Health & Human
`Services Administrative Law Judges.
`
`Board of Directors, Juvenile Diabetes Foundation, Amarillo
`
`Board of Directors, Amarillo Chapter, American Diabetes
`Association
`
`Health Reform Advisory Committee Member for
`Hon. Bill Sarpalius 13th District – Texas
`
`Board of Governors
`Northwest Texas Healthcare System, Amarillo
`
`Board of Directors, Texas Chapter
`American Association of Clinical Endocrinologists
`
`President , Texas Chapter
`American Association of Clinical Endocrinologists
`
`
`
`3
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
`2004 - 2014
`
`
`
`Director, Take Control of Your Diabetes Conference
`9/11/2004, 9/16/2006, 2/7/2009, 9/10/2011, 10/18/2014
`Amarillo Civic Center
`
`Session Co-Chair – American Diabetes Association 69th
`Scientific Sessions, New Orleans – “Advances in Our
`Understanding of Continuous Glucose Monitoring”
`
`Participant in AMA Meaningful Use comment meetings
` with CMS, representing the American Association of
`Clinical Endocrinologists
`
`Texas Diabetes Council - Advisor
`Texas Department of State Health Services
`Health Professional Advisory Committee
`Medical Professional Advisory Subcommittee
`
`
`
`
`
`
`
`
`
`
`2009
`
`
`2010
`
`
`
` 2010 - 2015
`
`
`
`
`
`
`
`
`Recent Honors:
`
`
`Who’s Who in Medicine and Healthcare 2nd - 7th editions 1998 – 2008
`
`
`
`
`
`
`
`Who’s Who in America, 55th – 62nd editions, 2001 - 2008
`
`Who’s Who in Science and Engineering, 2002 - 2006
`
`Fellow, American College of Endocrinology 2005
`
`Promise Honoree, Juvenile Diabetes Research Foundation, Amarillo, June 2005
`
`Texas Monthly “SuperDoctor” Texas Monthly Magazine, 2005 through 2019
`
`
`
`
`
`Selected Publications:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Impaired Perception of Inspiratory Resistive Loads in Diabetes Mellitus.
`American Review of Respiratory Disease, 132:4(2) A191, April 1986
`
`Diabetes Mellitus and Exercise. Panhandle Health 3:3 Summer 1992
`
`Transplantation and Diabetes Panhandle Health 9:4 Fall 1999
`
`How to Interpret Your Blood Test Results Medical Tests Sourcebook 2nd ed.,
`Joyce Brennfleck Shannon, editor. Omnigraphics Press, Detroit 2004
`
`Has the TSH “Normal Range” been set too high? Panhandle Health 14:1 Winter
`2003
`
`Obesity and Diabetes Panhandle Health 14:2 Spring 2004
`
`
`
`
`4
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
`
`‘The Fertile and Infertile Phases of the Menstrual Cycle are Signaled by Cervical-
`Vaginal Fluid Die Swell Functions’ Jian Wang, Ph.D., Stephen J. Usala, M.D.,
`Ph.D., Faye O’Brien-Usala, D.C., William C. Biggs, M.D., Mark W. Vaughn,
`Ph.D., and Gregory B. McKenna, Ph.D. The Endocrinologist
`November/December 2009 19:6 291-297
`
`The EHR Incentive Program and “Meaningful Use” AACE The First Messenger
`19:2 6-27 March/April 2010
`
`“The Elasticity of Cervical-vaginal Secretions is Abnormal in Polycystic Ovary
`Syndrome: Case Report of Five PCOS Women” Nabila Shamim, Stephen J.
`Usala, William C. Biggs, Gregory McKenna Indian Journal of Endocrinology
`and Metabolism - 2012 Nov-Dec; 16(6): 1019–1021
`
`“Vaginal Swab Levels of CA125 are Related to Time of Cycle in Ovulatory
`Women: a Pilot Study” , Stephen J. Usala, M.D., Ph.D., William C. Biggs, M.D.,
`Faye O’Brien-Usala, D.C. Journal of Reproductive Medicine 2015 Jul-Aug;60(7-
`8):287-9
`
`“Optimizing mHealth Technologies in Real-World Clinical Practices”, Pablo
`Mora, William C. Biggs, and Christopher G. Parkin. Clinical Diabetes 2019 July;
`37(3): 269-275
`
`
`
`Selected Recent Oral Presentations:
`
`
`Texas AACE Diabetes Management for Primary Care Physicians All-Day
`Program Speaker and Co-Director
`
`
`2007
`2008
`2009
`
`2010
`
`2011
`
`
`
`
`
`
`
`
`
`Amarillo
`South Padre Island
`Tyler
`Odessa
`Lubbock
`Waco
`El Paso
`
`
`
`
`
`
`
`2009 eClinicalWorks National Users Meeting
`
`Keynote Speaker General Session: “The Future of Healthcare”
`
`Las Vegas, Nevada
`
`2009 American Diabetes Association Scientific Sessions
`Co-chair: “Advances in Our Understanding of Continuous Glucose
`Monitoring”
`New Orleans, LA
`
`2010 “Office Management of Thyroid Nodules”
`Texas Medical Association Annual Meeting, Fort Worth
`
`eClinicalWorks National Users Meeting (Invited Speaker)
`“Clinical Analytics with IBM Cognos / EBO”
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`Orlando, Florida
`
`
`2011 American Association of Clinical Endocrinologists Annual Meeting
`
`“Optimizing Your EHR for Endocrine Practice”
`
`San Diego, California
`
`
`
`eClinicalWorks National Users Meeting
`Using eCW Technology to Minimize Paper, Increase Efficiency, Increase
`Quality of Care, and Improve Income
`Scottsdale, AZ
`
`
`2012 American Association of Clinical Endocrinologists Annual Meeting
`“Exploring Alternative Payment Mechanisms – The Patient Centered
`Medical Home”
`Philadelphia, Pennsylvania
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`eClinicalWorks National Users Meeting
`“Specialist Panel – Specialty Physicians Share Their Best Practices with
`eCW”
`Washington, DC
`
`
`
` 2013 American Association of Clinical Endocrinologists Annual Meeting
`
`“How Will Endocrinologists Be Paid - The Role of the Accountable Care
`Organization”
`Phoenix, Arizona
`
`
`
`
`
`
`
`
`eClinicalWorks National Users Meeting (Invited Speaker)
`“IT implementation in an Accountable Care Organization – HIE, Care
`Coordination, Clinical Analytics, Financial Analytics”
`San Antonio, Texas
`
`2014 HIMSS Texas annual meeting
`
`IT Challenges – Implementing a Physician Directed ACO in Amarillo, TX
`
`Dallas, Texas
`
`
`
`
`
`National Association of ACOs
`Putting the Pieces Together – A Physician Directed ACO in Amarillo, TX
`Baltimore, MD
`
`American Association of Clinical Endocrinologists Annual Meeting
`The Endocrinologist’s role in ACOs
`Las Vegas, NV
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2015
`
`
` 2016
`
`
`6
`
`
`
`PCMH and Shared Savings ACO Summit
`Achieving Success with a Physician Led ACO
`Nashville, TN
`
`
`HIMSS 15 – Chicago
`IT Challenges in a Physician Directed ACO
`
`American Association of Clinical Endocrinologists Annual Meeting
`Socioeconomic Forum – How does the endocrinologist fit into an ACO?
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
`
`
` 2017
`
`
`
`
`
`2018
`
`
`2019
`
`
`
`Orlando, FL
`
`HIMSS Texas annual meeting - San Antonio, Texas
`Implementing a Remote Glucose Monitoring Program using Internet Connected
`BG Meters and Care Coordinators in an Accountable Care Organization
`San Antonio, Texas
`
`eClinicalWorks National Users Conference – Nashville, TN
`Panel Discussion : “Impact of proposed CMS revisions to E&M codes”
`
`American Association of Clinical Endocrinologists Annual Meeting – Los
`Angeles CA – “Telehealth – Expanding Your Reach”
`
`
`
`Selected Recent and Current Clinical Trials
`
`Principal Investigator
`
`
`
`
`
`
`Sanofi
`
`EFC12405
`
`A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm,
`Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the
`Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With
`or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) /
`LixiLan-L
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`LPS14347
`
`A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to
`Assess the Clinical and Health Outcomes of Toujeo Compared to
`Commercially Available Basal Insulins for Initiation of Therapy in Insulin -
`naive Patients With Uncontrolled Type 2 Diabetes Mellitus
`
`
`
`AstraZeneca
`
`MB102-229
`
`MB102-230
`A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group,
`Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on
`to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus
`
`Dexcom
`
`DiaMonD
`Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes
`
`NovoNordisk
`
`NN9535-3625 SUSTAIN
`
`Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once
`Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve
`Subjects With Type 2 Diabetes
`
`
`
`7
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
`
`NN9535-3627 SUSTAIN
`
`NN1218-3852 ONSET
`
`Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination
`With Insulin Detemir in Adults With Type 1 Diabetes
`
`
`
`NN1218-3854 ONSET 5
`NN2211-3916 BEGIN
`
`Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes
`Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
`
`
`
`NN9211-3919 ADJUNCT
`
`The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the
`Treatment of Type 1 Diabetes
`
`
`
`
`
`NN1250-3995 IMPACT / SWITCH 1
`
`A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin
`Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1
`Diabetes
`
`NN9211-4083 ADJUNCT 2
`
`
`
`
`
`NN1218-4131 ONSET 8
`NN9924-4222 PIONEER 3
`NN9924-4234 PIONEER 5
`
`Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in
`Subjects With Type 2 Diabetes
`
`
`
`NN1250-4252
`
`A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin
`Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately
`Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01676
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
